Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Around $8 Million Bet On Zymeworks? Check Out These 3 Stocks Insiders Are Buying

Published 13/01/2023, 11:31
© Reuters.  Around $8 Million Bet On Zymeworks? Check Out These 3 Stocks Insiders Are Buying
IXIC
-
CMTL
-
ZYME
-

Benzinga - Although US stocks closed higher on Thursday, there were a few notable insider trades.

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.

Alvarium Tiedemann

  • The Trade: Alvarium Tiedemann Holdings, Inc. (NASDAQ: ALTI) 10% owner Pangaea Three-B, LP acquired a total of 176,202 shares an average price of $9.48. To acquire these shares, it cost around $1.45 million.
  • What’s Happening: The company’s shares gained around 3% over the past month.
  • What Alvarium Tiedemann Does: Alvarium Tiedemann Holdings Inc is an independent global wealth and asset manager providing entrepreneurs, multi-generational families, institutions, and emerging next-generation leaders with fiduciary capabilities as well as alternative investment strategies and advisory services.

Comtech Telecommunications

  • The Trade: Comtech Telecommunications Corp. (NASDAQ: CMTL) Director, Chairman, President and CEO Ken A Peterman acquired a total of 44,000 shares at an average price of $12.75. To acquire these shares, it cost around $560.94 thousand.
  • What’s Happening: Comtech, last month, was awarded 5G location services contract with Tier-1 MNO in Canada.
  • What Comtech Telecommunications Does: Comtech Telecommunications Corp is a provider of advanced communications solutions.
Don’t forget to check out our premarket coverage here

Check This Out: Fear & Greed Index Moves To 'Greed' Zone Following Inflation Report

Zymeworks

  • The Trade: Zymeworks Inc. (NASDAQ: ZYME) 10% owner Ecor Capital LLC bought a total of 1,026,300 shares at an average price of $7.67. To acquire these shares, it cost around $7.87 million.
  • What’s Happening: Zymeworks recently issued corporate update on key strategic priorities and outlook for 2023.
  • What Zymeworks Does: Zymeworks BC Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.